November 15, 2026
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

BREAKTHROUGH: Cuban drug Heberprot-P authorized for medical trials in the US

May 5, 2024

Heberprot-P, the only drug in the world that has reduced the amputation rate by up to 75 percent in patients with diabetic foot ulcers, has been approved by the US Food and Drug Administration (FDA) for the biotechnology company Discovery Therapeutics Caribe (DTC) to conduct the said study.

It is a phase-three protocol for a randomized, double-blind, placebo-controlled trial of the company’s leading product, according to a press release from the Biotechnological and Pharmaceutical Industries Business Group (BioCubaFarma).

According to its description, Heberprot-P contains recombinant human epidermal growth factor (rhEGF) to heal deep and complex neuropathic and ischemic diabetic foot ulcers, speeds up progressive and sustained healing, and reduces the risk of amputation.

Cuba’s Center for Genetic Engineering and Biotechnology (CIGB) is credited with developing Heberprot-P, the only therapy included in the comprehensive care program for Cuban diabetic patients, and the Good Diabetic Living Program in Venezuela for more than ten years.

Heberprot-P is also available in more than 20 countries and is the first time that it will be tested in US patients. It will be a leading option in the therapeutic arsenal for the severe condition of the diabetic foot.

In statements to Prensa Latina early this year, CIGB General Director Marta Ayala said that Heberprot-P is administered in Colombia, Türkiye, and Russia, has sanitary registrations in Arab countries, and Cuba is also working so that people from other nations can have access to it, considering that diabetes is a chronic disease present across the world.

She noted that more than 400,000 patients with diabetic foot ulcers have benefited from Heberprot-P since its initial approval by the Cuban regulatory agency in June 2006.

Ayala said that research into other formulations, including nanotechnology, will make it possible to administer Heberprot-P to treat other complex ulcers, such as pressure ulcers and venous ulcers caused by vascular disorders.

Dr. David Armstrong, a distinguished podiatric surgeon at the University of Southern California and a world-renowned diabetic foot ulcer researcher, emphasized the critical need for innovative therapies.

“There is an urgent need for treatments that can halt the progression of diabetic foot ulcers before amputation becomes the inevitable solution. Historically, treatment options have been limited, but we have hope with the introduction of advanced therapies such as intralesional rhEGF.”

DTC Co-founder and President Lee Weingart commented, “We are pleased to start the next stage of intralesional rhEGF’s global journey in the United States, which will help understand the clinical profile of this biologic product within the regulatory framework, and use the extensive international clinical experience.

It is estimated that more than 37 million US citizens have diabetes; up to 34 percent of them will suffer from diabetic foot ulcers, and about 154,000 patients with non-healing ulcers undergo amputation.

In addition, nearly half of patients who undergo lower extremity amputations related to diabetic foot ulcers do not survive more than five years, Charles Zelen, a doctor of Podiatric Medicine, explained.

The authorization for the Cuban-made injectable drug Heberprot-P to begin phase three of clinical trials in the United States is a new achievement by Cuban scientists and researchers from the biotechnological and pharmaceutical industry.

Prensa Latina

Museveni Calls on Rwenzururu Kingdom to Champion Wealth Creation

5 hours ago

Israel Alerts US to Alleged Drone Plot Targeting Trump and Senior Officials – Reports

5 hours ago

Eisenkot Accuses Netanyahu of Political Stalling, Says New Israeli Government Will Be Formed

6 hours ago

China Tests 10-Tonne Electric Passenger Plane Capable of Autonomous Flight

6 hours ago

Egypt Sacks World Cup Coach Hossam Hassan After Wives’ Bar Brawl

6 hours ago

Museveni Calls on Rwenzururu Kingdom to Champion Wealth Creation

Israel Alerts US to Alleged Drone Plot Targeting Trump and Senior Officials – Reports

Kremlin Confirms First-Ever Putin-Xi-Trump Trilateral Summit in China on November 19

EU Urges Israel to Reopen Gaza Crossings as Flooding and Winter Conditions Worsen Humanitarian Crisis

Kagame, Tshisekedi in Cambodia for Francophonie Summit

Rwanda Questions DRC’s Support for Romanian Candidate in Francophonie Leadership Race

Museveni Calls on Rwenzururu Kingdom to Champion Wealth Creation

5 hours ago
Israel Alerts US to Alleged Drone Plot Targeting Trump and Senior Officials – Reports

5 hours ago
Eisenkot Accuses Netanyahu of Political Stalling, Says New Israeli Government Will Be Formed

6 hours ago
China Tests 10-Tonne Electric Passenger Plane Capable of Autonomous Flight

6 hours ago
Egypt Sacks World Cup Coach Hossam Hassan After Wives’ Bar Brawl

6 hours ago
Ex US Police Officer Sentenced to 3 Life Terms, Chemical Castration for Raping Children

6 hours ago
Kremlin Confirms First-Ever Putin-Xi-Trump Trilateral Summit in China on November 19

8 hours ago
EU Urges Israel to Reopen Gaza Crossings as Flooding and Winter Conditions Worsen Humanitarian Crisis

9 hours ago
Kagame, Tshisekedi in Cambodia for Francophonie Summit

9 hours ago
Apostle Lubega Draws Business Leaders to Sold-Out Phaneroo Symposium Amid Pastors’ Controversy

10 hours ago
‘You Opened Doors for Us’: Bigirimana’s Mentees Pay Tribute as He Retires

11 hours ago
Rwanda Questions DRC’s Support for Romanian Candidate in Francophonie Leadership Race

12 hours ago

Eisenkot Accuses Netanyahu of Political Stalling, Says New Israeli Government Will Be Formed

6 hours ago

Kremlin Confirms First-Ever Putin-Xi-Trump Trilateral Summit in China on November 19

8 hours ago

‘Let Us Move Forward’: Namuganza Speaks After Winning Election Court Battle

14 hours ago

New Israeli Leadership Bid: Eisenkot Rules Out Using Security for Political Gain

1 day ago

+256774552385 | info@ugdiplomat.com

Copyright © 2026 UG Diplomat -Product of CURRENTARC MEDIA

Views: 2,942